CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

NCT06078306 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

B Acute Lymphoblastic Leukemia
Ph-Negative ALL
High Risk Acute Lymphoblastic Leukemia

Interventions

DRUG: Azacitidine Injection
DRUG: Venetoclax
DRUG: CD19CD22 CAR-T

Sponsor

The First Affiliated Hospital of Soochow University